<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02803229</url>
  </required_header>
  <id_info>
    <org_study_id>7280</org_study_id>
    <secondary_id>U54DA037842-01</secondary_id>
    <nct_id>NCT02803229</nct_id>
  </id_info>
  <brief_title>Treatment of Cannabis Use Disorder Among Adults With Comorbid Attention-Deficit/Hyperactivity Disorder</brief_title>
  <acronym>MJ-ADHD</acronym>
  <official_title>Treatment of Cannabis Use Disorder Among Adults With Comorbid Attention-Deficit/Hyperactivity Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The proposed protocol is a double-blind, placebo-controlled outpatient study of the safety&#xD;
      and benefit of Extended-release mixed amphetamine salt (Adderall-XR, MAS-XR) in the treatment&#xD;
      of individuals with Cannabis Use Disorder (CUD) and Attention-deficit/Hyperactivity Disorder&#xD;
      (ADHD). The investigators plan to enroll 50 and randomize 40 of these patients in the trial.&#xD;
      The primary objective of the study is to determine the efficacy of MAS-XR in promoting&#xD;
      cannabis abstinence among individuals with CUD and in promoting a decrease of ADHD symptoms.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ADHD is common in substance use disorder patients in general and cannabis use disorder (CUD)&#xD;
      in particular, occurring at rates substantially greater than in the general population. A&#xD;
      meta-analysis found that approximately 23% of substance abusers seeking treatment have&#xD;
      childhood and/or adult ADHD. Moreover, ADHD was overrepresented in adults with CUD compared&#xD;
      to other substance use disorder patients seeking treatment. The importance in treating CUD&#xD;
      individuals who also have ADHD is underscored by findings demonstrating that individuals with&#xD;
      co-occurring ADHD and substance use disorders are a particularly intractable group: they&#xD;
      exhibit earlier onset of use, more severe use, a more complicated pattern of&#xD;
      remission/relapse, and poorer treatment outcomes relative to those without ADHD. Yet, to&#xD;
      date, ADHD individuals with CUD have not been adequately studied. The investigators have&#xD;
      found that in their treatment research studies targeting cannabis dependence that a&#xD;
      substantial percentage (35%) have screened positive for adult ADHD, rates that are higher&#xD;
      than participants in their cocaine use disorder clinical trial and almost 8x greater than&#xD;
      rates found in the general population. Thus, this appears to be a sizable cannabis-abusing&#xD;
      group warranting much greater clinical attention than they are currently receiving.&#xD;
&#xD;
      The goal is to demonstrate feasibility, tolerability, and estimate effect size for purposes&#xD;
      of planning future more definitive trials. Because of the research team's extensive&#xD;
      experience in working with stimulant medication in treating ADHD in cocaine-dependent&#xD;
      populations, the large effect size of amphetamine in treating adult ADHD, and notable&#xD;
      reduction in cocaine use and ADHD symptoms in cocaine-dependent ADHD adults, the&#xD;
      investigators will explore the efficacy of Adderall-XR (MAS-XR) for the treatment of cannabis&#xD;
      use disorder and ADHD. The study is a 12 week placebo controlled double-blind trial. The&#xD;
      maximum maintained dose will be 80 mg of MAS-XR daily.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 2016</start_date>
  <completion_date type="Actual">June 2020</completion_date>
  <primary_completion_date type="Actual">June 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Marijuana Abstinence</measure>
    <time_frame>Change from baseline compared to last 2 weeks of the 12 week study on maintained dose (weeks 10 and 11 for completers) or last 2 weeks of participants' participation during the study for participants who drop out of the study before weeks 10 and 11</time_frame>
    <description>Number of participants who achieve abstinence from marijuana during the last two weeks of the trial as recorded by the Timeline Followback method and confirmed by urine toxicology.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Reduction in ADHD Symptoms</measure>
    <time_frame>Change from baseline compared to last week of trial on maintained dose during the 12 week trial (week 11 for completers) or last week of participants' participation during the 12 week trial for those who drop out of study prior to week 11.</time_frame>
    <description>The primary ADHD outcome measure will be the number of individuals who achieve at least a 30% reduction in symptom severity as measured by the Adult ADHD Interview Rating Scale (AISRS).</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">33</enrollment>
  <condition>Cannabis Use Disorder</condition>
  <condition>Attention-deficit/Hyperactivity Disorder</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>matched Placebo arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adderall-XR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adderall-XR (MAS-XR) 80 mg/day maximum maintenance dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adderall-XR</intervention_name>
    <arm_group_label>Adderall-XR</arm_group_label>
    <other_name>Extended-release mixed amphetamine salt</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matched placebo</intervention_name>
    <description>matched placebo provided for placebo arm</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Individuals who meet criteria for cannabis use disorder (CUD) and report that&#xD;
             marijuana is their primary drug of abuse&#xD;
&#xD;
          -  Individuals must report using marijuana at least 5 days a week over the past 28 days&#xD;
             and have a positive urine test for tetrahydrocannabinol (THC) on the day of study&#xD;
             entry&#xD;
&#xD;
          -  Individuals must meet Diagnostic and Statistical Manual 5th ed. (DSM-5) criteria for&#xD;
             adult ADHD&#xD;
&#xD;
          -  Individuals who score &gt; 22 on the adult ADHD Investigator Symptom Rating Scale (AISRS)&#xD;
&#xD;
          -  Individuals between the ages of 18-65 capable of giving informed consent and capable&#xD;
             of complying with study procedures&#xD;
&#xD;
          -  Women of child-bearing age will be included if they: a) are not pregnant, b) agree to&#xD;
             use an effective method of contraception, c) agree not to become pregnant during the&#xD;
             study and d) are not breastfeeding. To confirm this, urine pregnancy tests will be&#xD;
             repeated every month after screening. Women will be provided a full explanation of the&#xD;
             potential dangers of pregnancy while taking MAS-XR. If a woman becomes pregnant, she&#xD;
             will be taken off medication and continue standard treatment. At the end of the study,&#xD;
             patients will be offered treatment until an appropriate referral can be made to a&#xD;
             community clinic.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Individuals meeting DSM-5 criteria for schizophrenia, schizoaffective illness,&#xD;
             psychotic disorder other than transient psychosis due to drug abuse, current major&#xD;
             depression, bipolar illness or psychiatric disorders (other than substance abuse)&#xD;
             which require psychiatric intervention or would interfere with study participation&#xD;
&#xD;
          -  Individuals who are medically unstable based on laboratory tests, electrocardiogram,&#xD;
             medical history, physical examination that would make participation hazardous&#xD;
&#xD;
          -  Use of synthetic cannabinoids in the past month and meeting CUD diagnosis based on&#xD;
             synthetic cannabinoids use alone in the past year&#xD;
&#xD;
          -  Individuals with liver enzyme function tests greater than 3 times normal&#xD;
&#xD;
          -  Individuals with significant current suicidal risk&#xD;
&#xD;
          -  Individuals with systolic blood pressure &gt; 140; diastolic blood pressure &gt;90; pulse&#xD;
             &gt;100&#xD;
&#xD;
          -  Individuals who are cognitively impaired to impede study participation&#xD;
&#xD;
          -  Nursing mothers and pregnant women&#xD;
&#xD;
          -  Individuals who are physiologically dependent on any other drugs (excluding nicotine)&#xD;
             that would require a medical intervention&#xD;
&#xD;
          -  Individuals with known sensitivity/allergy to MAS-XR or amphetamine analogs&#xD;
&#xD;
          -  Individuals currently being prescribed psychotropic medication (including sleep&#xD;
             medication)&#xD;
&#xD;
          -  Individuals with history of seizures&#xD;
&#xD;
          -  Individuals who are mandated to treatment&#xD;
&#xD;
          -  Individuals with a history of amphetamine use disorders, including amphetamines such&#xD;
             as methamphetamine and methylenedioxymethamphetamine (MDMA).&#xD;
&#xD;
          -  Individuals with a current cocaine use disorder&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Frances R Levin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>New York Psychiatric Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York Psychiatric Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>June 9, 2016</study_first_submitted>
  <study_first_submitted_qc>June 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 16, 2016</study_first_posted>
  <results_first_submitted>March 16, 2021</results_first_submitted>
  <results_first_submitted_qc>March 16, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">April 9, 2021</results_first_posted>
  <last_update_submitted>March 16, 2021</last_update_submitted>
  <last_update_submitted_qc>March 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>New York State Psychiatric Institute</investigator_affiliation>
    <investigator_full_name>Frances R Levin</investigator_full_name>
    <investigator_title>Research Psychiatrist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperkinesis</mesh_term>
    <mesh_term>Disease</mesh_term>
    <mesh_term>Marijuana Abuse</mesh_term>
    <mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amphetamine</mesh_term>
    <mesh_term>Adderall</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 7, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/29/NCT02803229/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 29, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/29/NCT02803229/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>The study contained a one week placebo lead-in prior to randomization. Three participants were excluded due to being a placebo-responder and two participants were lost to follow-up during this lead-in week.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>matched Placebo arm&#xD;
Matched placebo: matched placebo provided for placebo arm</description>
        </group>
        <group group_id="P2">
          <title>Adderall-XR</title>
          <description>Adderall-XR (MAS-XR) 80 mg/day maximum maintenance dose&#xD;
Adderall-XR</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Randomized participants</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>matched Placebo arm&#xD;
Matched placebo: matched placebo provided for placebo arm</description>
        </group>
        <group group_id="B2">
          <title>Adderall-XR</title>
          <description>Adderall-XR (MAS-XR) 80 mg/day maximum maintenance dose&#xD;
Adderall-XR</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="15"/>
            <count group_id="B2" value="13"/>
            <count group_id="B3" value="28"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.3" spread="9.5"/>
                    <measurement group_id="B2" value="32.4" spread="11.2"/>
                    <measurement group_id="B3" value="32.9" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>baseline cannabis use</title>
          <description>Number of days of self reported cannabis use during 28 days prior to study enrollment.</description>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.9" spread="1.7"/>
                    <measurement group_id="B2" value="27.3" spread="1.1"/>
                    <measurement group_id="B3" value="27.1" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Marijuana Abstinence</title>
        <description>Number of participants who achieve abstinence from marijuana during the last two weeks of the trial as recorded by the Timeline Followback method and confirmed by urine toxicology.</description>
        <time_frame>Change from baseline compared to last 2 weeks of the 12 week study on maintained dose (weeks 10 and 11 for completers) or last 2 weeks of participants' participation during the study for participants who drop out of the study before weeks 10 and 11</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>matched Placebo arm&#xD;
Matched placebo: matched placebo provided for placebo arm</description>
          </group>
          <group group_id="O2">
            <title>Adderall-XR</title>
            <description>Adderall-XR (MAS-XR) 80 mg/day maximum maintenance dose&#xD;
Adderall-XR</description>
          </group>
        </group_list>
        <measure>
          <title>Marijuana Abstinence</title>
          <description>Number of participants who achieve abstinence from marijuana during the last two weeks of the trial as recorded by the Timeline Followback method and confirmed by urine toxicology.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Reduction in ADHD Symptoms</title>
        <description>The primary ADHD outcome measure will be the number of individuals who achieve at least a 30% reduction in symptom severity as measured by the Adult ADHD Interview Rating Scale (AISRS).</description>
        <time_frame>Change from baseline compared to last week of trial on maintained dose during the 12 week trial (week 11 for completers) or last week of participants' participation during the 12 week trial for those who drop out of study prior to week 11.</time_frame>
        <population>One participant in each arm did not have any follow-up AISRS scores, so they were not included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>matched Placebo arm&#xD;
Matched placebo: matched placebo provided for placebo arm</description>
          </group>
          <group group_id="O2">
            <title>Adderall-XR</title>
            <description>Adderall-XR (MAS-XR) 80 mg/day maximum maintenance dose&#xD;
Adderall-XR</description>
          </group>
        </group_list>
        <measure>
          <title>Reduction in ADHD Symptoms</title>
          <description>The primary ADHD outcome measure will be the number of individuals who achieve at least a 30% reduction in symptom severity as measured by the Adult ADHD Interview Rating Scale (AISRS).</description>
          <population>One participant in each arm did not have any follow-up AISRS scores, so they were not included in the analysis.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks of trial or length of participation.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>matched Placebo arm&#xD;
Matched placebo: matched placebo provided for placebo arm</description>
        </group>
        <group group_id="E2">
          <title>Adderall-XR</title>
          <description>Adderall-XR (MAS-XR) 80 mg/day maximum maintenance dose&#xD;
Adderall-XR</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation (Afib)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>hypertension</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>anorexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>insomnia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>nervousness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>erectile dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>irritability</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>jittery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>weight loss</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>arm numbness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>backache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>cramps</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>psychomotor agitation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>tremor</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>shortness of breath</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="13"/>
              </event>
              <event>
                <sub_title>upper respiratory infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Frances R Levin, MD</name_or_title>
      <organization>New York State Psychiatric Institute</organization>
      <phone>6467746137</phone>
      <email>frl2@cumc.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

